Kiyoshi Yoshimura

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.

Journal: International journal of clinical oncology

Published: March 18, 2026

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP.

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP.

Journal: Frontiers in immunology

Published: March 17, 2026

Correction: Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Correction: Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Journal: Frontiers in immunology

Published: March 10, 2026

Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

Journal: Scientific reports

Published: February 05, 2026

Association of Intratumoral Macrophage Subsets with Treatment Outcomes in Patients with Stage IV Solid Tumors.

Association of Intratumoral Macrophage Subsets with Treatment Outcomes in Patients with Stage IV Solid Tumors.

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: February 05, 2026

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 31, 2025

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Journal: Biomedicines

Published: October 30, 2025

Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial-mesenchymal transition via histamine H1 receptor inverse agonism.

Cetirizine suppresses cancer-associated fibroblast-mediated fibrotic remodeling and epithelial-mesenchymal transition via histamine H1 receptor inverse agonism.

Journal: Breast cancer research : BCR

Published: October 16, 2025

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Journal: Cancers

Published: June 12, 2025

Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study.

Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study.

Journal: Frontiers in immunology

Published: June 03, 2025

Intestinal and esophageal microbiota in esophageal cancer development and treatment.

Intestinal and esophageal microbiota in esophageal cancer development and treatment.

Journal: Gut microbes

Published: May 16, 2025

Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.

Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.

Journal: Frontiers in oncology

Published: April 18, 2025

Showing 1-12 of 94

Last Updated: 09/26/2026